Literature DB >> 16136016

Treatment of acute agitation in psychotic disorders.

Pavel Mohr1, Ján Pecenák, Jaromír Svestka, Dave Swingler, Tamás Treuer.   

Abstract

Several psychotic disorders, including schizophrenia, may be associated with symptoms of acute agitation and aggression. While drug treatment of agitation is often essential, non-pharmacological interventions, both environmental and behavioral, also play important roles in the complex management of agitated patients. The most extensively used psychotropic drugs are parenteral formulas of conventional antipsychotics and benzodiazepines. Recently, injection forms of two second generation antipsychotics, olanzapine and ziprasidone, have become available. Both drugs have shown adequate efficacy and tolerability in several double-blind trials of intramuscular administration in acutely agitated psychotic patients. Compared to conventional medication, injection forms of the new antipsychotics may have a faster onset of action and more favorable profile of adverse events. Alternative approaches to injection administration include liquid drug formula, orally disintegrating tablets and wafers, treatment initiation with high doses, or rapid dose escalation. Evidence suggests that second-generation antipsychotics should be among the first-line choices in the treatment of agitation in acute psychosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136016

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  12 in total

Review 1.  Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Melanie J Brooke-Powney; Xue Li; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

Review 2.  Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related Articles.

Authors:  Maryam Ziaei; Ali Massoudifar; Ali Rajabpour-Sanati; Ali-Mohammad Pourbagher-Shahri; Ali Abdolrazaghnejad
Journal:  Adv J Emerg Med       Date:  2018-11-29

Review 3.  Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Salwan Jajawi; Styliani Spyridi; Kamlaj Sayal; Mahesh B Jayaram
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

Review 4.  Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review.

Authors:  Xin Yu; Christoph U Correll; Yu-Tao Xiang; Yifeng Xu; Jizhong Huang; Fude Yang; Gang Wang; Tianmei Si; John M Kane; Prakash Masand
Journal:  Shanghai Arch Psychiatry       Date:  2016-10-25

5.  Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia.

Authors:  Jenna Roberts; Alfredo Gracia Canales; Sophee Blanthorn-Hazell; Anca Craciun Boldeanu; Davneet Judge
Journal:  BMC Psychiatry       Date:  2018-04-16       Impact factor: 3.630

6.  Acute interventions for aggression and agitation in psychosis: study protocol for a systematic review and network meta-analysis.

Authors:  Edoardo G Ostinelli; Armando D'Agostino; Farhad Shokraneh; Georgia Salanti; Toshi A Furukawa
Journal:  BMJ Open       Date:  2019-10-10       Impact factor: 2.692

Review 7.  The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review.

Authors:  Maurizio Pompili; Giuseppe Ducci; Alessandro Galluzzo; Gianluca Rosso; Claudia Palumbo; Domenico De Berardis
Journal:  Int J Environ Res Public Health       Date:  2021-04-20       Impact factor: 3.390

8.  Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia - Japan postmarketing surveillance study.

Authors:  Hideaki Katagiri; Masanori Taketsuna; Shinpei Kondo; Kenta Kajimoto; Etsuko Aoi; Yuka Tanji
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-12       Impact factor: 2.570

9.  Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia.

Authors:  Hideaki Katagiri; Masanori Taketsuna; Shinpei Kondo; Kenta Kajimoto; Etsuko Aoi; Yuka Tanji
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-23       Impact factor: 2.570

10.  Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness.

Authors:  Andrew M Williams
Journal:  Ment Health Clin       Date:  2018-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.